6-溴-4-甲基喹啉-3-羧酸 | 1095010-36-8

• 物质功能分类: 医药中间体 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-溴-4-甲基喹啉-3-羧酸
• 英文名称: 6-bromo-4-methylquinoline-3-carboxylic acid
• CAS: 1095010-36-8
• 化学式: C₁₁H₈BrNO₂
• 分子量: 266.094
• InChiKey: JWZOKLNGXQIFLK-UHFFFAOYSA-N

物化性质

• 沸点：
  411.3±40.0 °C(Predicted)
• 密度：
  1.644±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26
• 危险类别码：
  R22,R36
• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  6-溴-4-甲基喹啉-3-羧酸 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 生成 6-bromo-3-isocyanato-4-methylquinoline
  参考文献：
  名称：

  [EN] INHIBITORS OF MALT1 AND USES THEREOF
  [FR] INHIBITEURS DE MALT1 ET LEURS UTILISATIONS

  摘要：

  本文提供了一些抑制MALT1的化合物，MALT1是一种蛋白质，其活性负责某些癌症（如激活的B细胞弥漫性大B细胞淋巴瘤（ABC-DLBCL））中的NF-κΒ信号。还提供了包含这些化合物的药物组合物和试剂盒，以及使用这些化合物在受试者中治疗MALT1相关疾病和疾病（如癌症）的方法，通过给予本文描述的化合物和/或组合物。

  公开号：

  WO2018165385A1

文献信息

• Compounds for MALT1 degredation
  申请人：Cornell University

  公开号：US10689366B2

  公开（公告）日：2020-06-23

  Provided herein are bifunctional compounds that inhibit MALT1 and/or promote targeted ubiquitination for the degradation of MALT1. In particular, provided are compounds that can bind MALT1, a protein whose activity is responsible for constitutive NF-KB signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)), and can assist in its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon, VHL), which can ubiquitinate MALT1, marking it for proteasome degradation. Also provided are pharmaceutical compositions comprising the bifunctional compounds, methods of treating cancer with the bifunctional compounds, methods of promoting the degradation of MALT1, and methods of binding E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.

  本文提供了抑制 MALT1 和/或促进靶向泛素化以降解 MALT1 的双功能化合物。特别是，所提供的化合物可结合 MALT1（其活性在某些癌症（如活化 B 细胞弥漫性大 B 细胞淋巴瘤（ABC-DLBCL））中负责组成型 NF-KB 信号转导的蛋白质），并可通过招募 E3 泛素连接酶（如 Cereblon、VHL）协助其降解，该连接酶可泛素化 MALT1，将其标记为蛋白酶体降解。还提供了包含双功能化合物的药物组合物、用双功能化合物治疗癌症的方法、促进MALT1降解的方法，以及通过施用本文所述化合物或组合物在受试者体内结合E3泛素连接酶活性的方法。
• Inhibitors of MALT1 and uses thereof
  申请人：Cornell University

  公开号：US11248007B2

  公开（公告）日：2022-02-15

  Provided herein are compounds that inhibit MALT1, a protein whose activity is responsible for constitutive NF-κB signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating MALT1-related diseases and disorders (e.g., cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.

  本文提供了抑制 MALT1 的化合物，MALT1 是一种蛋白质，其活性在某些癌症（如活化 B 细胞弥漫性大 B 细胞淋巴瘤（ABC-DLBCL））中负责组成型 NF-κB 信号转导。此外，还提供了包含所述化合物的药物组合物和试剂盒，以及通过施用所述化合物和/或组合物，用所述化合物治疗受试者MALT1相关疾病和失调（如癌症）的方法。
• COMPOUNDS FOR MALT1 DEGRADATION
  申请人：Cornell University

  公开号：US20190263785A1

  公开（公告）日：2019-08-29

  Provided herein are bifunctional compounds that inhibit MALT1 and/or promote targeted ubiquitination for the degradation of MALT1. In particular, provided are compounds that can bind MALT1, a protein whose activity is responsible for constitutive NF-KB signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)), and can assist in its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon, VHL), which can ubiquitinate MALT1, marking it for proteasome degradation. Also provided are pharmaceutical compositions comprising the bifunctional compounds, methods of treating cancer with the bifunctional compounds, methods of promoting the degradation of MALT1, and methods of binding E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.
• INHIBITORS OF MALT1 AND USES THEREOF
  申请人：Cornell UNiversity

  公开号：US20200385405A1

  公开（公告）日：2020-12-10

  Provided herein are compounds that inhibit MALT1, a protein whose activity is responsible for constitutive NF-κB signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating MALT1-related diseases and disorders (e.g., cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.